Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Top Cited Papers
- 24 June 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Rheumatology
- Vol. 2 (8), e474-e484
- https://doi.org/10.1016/s2665-9913(20)30173-9
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Trial of Tocilizumab in Giant-Cell ArteritisThe New England Journal of Medicine, 2017
- BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adultsThorax, 2016
- Potential Sources of Inter-Subject Variability in Monoclonal Antibody PharmacokineticsClinical Pharmacokinetics, 2016
- Sequential organ failure assessment scoring and prediction of patient's outcome in Intensive Care Unit of a tertiary care hospitalJournal of Anaesthesiology Clinical Pharmacology, 2016
- Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjectsInternational journal of clinical pharmacology and therapeutics, 2013
- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal AntibodiesClinical Pharmacokinetics, 2013
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Interleukin-6 inhibitors in the treatment of rheumatoid arthritisTherapeutics and Clinical Risk Management, 2008
- The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritisRheumatic Disease Clinics of North America, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987